Table 2.
Kidney outcome of the validation cohort according to histopathologic class
| Kidney Outcome Parameters | Focal, n=52 | Crescentic, n=37 | Mixed, n=39 | Sclerotic, n=17 | P Value |
|---|---|---|---|---|---|
| eGFR1, ml/min per 1.73 m2, mean ± SDa | 61±24 | 37±21 | 38±21 | 20±16 | <0.001 |
| ΔeGFR1, ml/min per 1.73 m2, mean ± SDa,b | 11±21 | 21±19 | 10±15 | 0±8 | 0.003 |
| eGFR5, ml/min per 1.73 m2, mean ± SDc | 60±21 | 35±20 | 37±24 | 19±20 | <0.001 |
| ΔeGFR5, ml/min per 1.73 m2, mean ± SDb,c | 8±24 | 19±23 | 10±20 | −1±14 | 0.04 |
| Kidney relapse (%) | 20 (40) | 14 (40) | 11 (29) | 3 (19) | 0.33 |
| Kidney failure (%) | 1 (2) | 9 (24) | 6 (15) | 8 (47) | <0.001 |
| Death (%) | 15 (29) | 15 (41) | 9 (23) | 6 (35) | 0.40 |
a
(Δ)eGFR1 was available in 132 patients.
b
ΔeGFR at a time point was defined as the difference between the eGFR at that time point and eGFR at baseline.
c
(Δ)eGFR5 was available in 113 patients.